Going Back to the Biology of FGF21: New Insights.


Journal

Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516

Informations de publication

Date de publication:
08 2019
Historique:
received: 18 04 2019
revised: 29 05 2019
accepted: 30 05 2019
pubmed: 30 6 2019
medline: 28 7 2020
entrez: 29 6 2019
Statut: ppublish

Résumé

Fibroblast growth factor 21 (FGF21) is a protein highly synthesized in the liver that exerts paracrine and endocrine control of many aspects of energy homeostasis in multiple tissues. In preclinical models of obesity and type 2 diabetes, treatment with FGF21 improves glucose homeostasis and promotes weight loss, and, as a result, FGF21 has attracted considerable attention as a therapeutic agent for the treatment of metabolic syndrome in humans. An improved understanding of the biological role of FGF21 may help to explain why its therapeutic potential in humans has not been fully realized. This review will cover the complexities in FGF21 biology in rodents and humans, with emphasis on its role in protection from central and peripheral facets of obesity.

Identifiants

pubmed: 31248786
pii: S1043-2760(19)30106-7
doi: 10.1016/j.tem.2019.05.007
pii:
doi:

Substances chimiques

KLB protein, human 0
Membrane Proteins 0
fibroblast growth factor 21 0
Fibroblast Growth Factors 62031-54-3
Klotho Proteins EC 3.2.1.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-504

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M001555/1
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Jo E Lewis (JE)

Institute of Metabolic Sciences and MRC-Metabolic Diseases Unit, University of Cambridge, Cambridge, CB0 0QQ, UK.

Francis J P Ebling (FJP)

MRC-ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, UK.

Ricardo J Samms (RJ)

Lilly Research Laboratories, Indianapolis, IN, USA.

Kostas Tsintzas (K)

MRC-ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, UK. Electronic address: kostas.tsintzas@nottingham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH